Русский
Malaria chemoprophylaxis during a long-term stay in an endemic area: experience with mefloquine and chloroquine
DOI: https://dx.doi.org/10.18565/epidem.2020.10.2.84-9
Solovyev A.I., Uskov A.N., Moskalev A.V.
1) S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; 2) Pediatric Research and Clinical Center for Infectious Diseases, Federal Biomedical Agency, Saint Petersburg, Russia
Subjects and methods. The authors present the results of following up the armed forces personnel from the Russian aviation group of the United Nations peace-keeping mission in Angola in 1996-1997 and used malaria chemoprophylaxis with mefloquine (250 mg once a week) and chloroquine (300 mg once a week). The military servicemen aged 22 to 53 years were followed up for 6 to 12 months.
Results. At 4 months after starting medication administration, the proportion of people with signs of the hypersensitivity of mefloquine and chloroquine was 29.7 and 8.3%, respectively. By the end of the 5th month, that was 35.1 and 10.7%, respectively. The persons sensitive to mefloquine had weakness, nausea, sleep disturbance, signs of depression, and a decline in visual acuity. Weakness, short-lasting headache, tinnitus, and decreased appetite were observed in those who took chloroquine.
Conclusion. When choosing a malaria chemoprophylaxis scheme, it is necessary to take into account individual drug sensitivity and the length of stay in an endemic area. As a rule, a continuous cycle of chemoprophylaxis should be planned for a period of not more than 3–4 months. The package of antimalarial measures should additionally include measures to reduce the risk of infection, to protect against vector attacks, and to ensure early detection and effective treatment in infected people.
Literature
1. Никитин А.Ф., Соловьев А.И., Усков А.Н., Грашин Р.А. и др. Эпидемическая ситуация по малярии на территории Западной Африки в зоне действия российского контингента миротворческих сил ООН. Вестник Российской военно-медицинской академии 2002; 8(2): 28–30. Nikitin A.F., Solovev A.I. Uskov A.N., Grashin R.A. at al. [Epidemic situation of malaria in West Africa in the Russian contingent operational zone of the UN peacekeeping forces]. Vestnik Rossiyskoy voyenno-meditsinskoy akademii 2002; 8(2): 28–30. (In Russ.). 2. Перепелкин В.С., Щербина В.П., Никитин А.Ф. Эпидемиология и профилактика малярии в горно-пустынной местности с жарким климатом. Воен.-мед. журн. 1988; 309(6): 39–41. Perepelkin V.S., Scherbina V.P., Nikitin A.F. [Epidemiology and prevention of malaria in mountainous and desert areas with a hot climate]. Voenno-meditsinskiу zhurnal 1988; 309(6): 39–41. (In Russ.) 3. Knobloch J.U. Long-term malaria prophylaxis for travelers. J. Travel. Med. 2004; 11(6): 374–8. DOI: https://doi.org/10.2310/7060.2004.1920 4. Chou A., Chevli C., Fitch R. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry 1980; 19(8): 1543–9. DOI: 10.1021/bi00549a600. 5 Verdier F., Bras J., Clavier F., Hatin I., Blayo M.-C. Chloroquine uptake by Plasmodium falciparum-infected human erythrocytes during in vitro culture and its relationship to chloroquine resistance. Antimicrob. Agents. Chemother. 1985; 27(4): 561–4. DOI: 10.1128/AAC.27.4.561. 6. Hasin T., Davidovitch N., Cohen R., Dagan T. еt al. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. N. Engl. J. Med. 2006; 355(2): 148–55. DOI: 10.1056/NEJMoa053884 7. Brumbaugh M., Price P., Fagan N., Hsieh H. Psychotic mania associated with mefloquine in a bipolar patient. South. Med. J. 2008; 101(5): 550–1. DOI: 10.1097/SMJ.0b013e318167a9e2 8. Telgt D.S., Ven A.J., Schimmer B., Droogleever-Fortuyn H.A., Sauerwein R.W. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann. Pharmacother. 2005; 39(3): 551–4. DOI: http://dx.doi.org/10.1345/aph.1E409 9. Rabar D., Combemale P., Peyron F. Doxycycline-Induced Photo-onycholysis. J. Travel Med. 2004; 11(6): 386–7. DOI: https://doi.org/ 10.2310/7060.2004.19210 10. Tabibian J.H., Gutierrez M.A. Doxycycline-induced pseudotumor cerebri. South. Med. J. 2009; 102(3): 310–1. DOI: https://doi.org/10.1097/SMJ. 0b013e31818f98f0 11. Lobel H.O., Miani M., Eng T., Bernard K.W. еt al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341(8849): 848–51. DOI: https://doi.org/10.1016/0140-6736(93)93058-9 12. Yelmo S., Morera-Fumero A., Henry M., Renshaw A., Gracia-Marco R. Mania associated with mefloquine prophylaxis. J. Clin. Psychopharmacol. 2010; 30(3): 339–41. DOI: 10.1097/JCP.0b013e3181de80f8. 13. Devaux C.A., Rolain J.-M., Colson P., Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int. J. Antimicrob. Agents 2020. https://doi.org/10.1016/j.ijantimicag. 2020.105938 14 Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. at al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 2020. https://doi.org/10.1093/cid/ciaa237
About the Autors
Information about the authors:
Alexey I. Solovev, MD, Professor, Department of Biology, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; e-mail: solopiter@gmail.com; ORCID: https:// orcid.org/0000-0002-3731-1756
Alexander N. Uskov, MD, Deputy Director of Research in the Development and Coordination of National and International Projects, Pediatric Research and Clinical Center for Infectious Diseases, Federal Biomedical Agency, Saint Petersburg, Russia, e-mail: aouskov@gmail.com; ORCID: https://orcid.org/0000-0003-3185-516X
Prof. Alexander V. Moskalev, MD, Department of Biology, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; e-mail: alexmav195223@ yandex. ru; ORCID: https://orcid.org/0000-0002-3403-3850.
Similar Articles
